Psychedelics and Trauma

This is a past event

Event Description

Psychedelic substances such as psilocybin, MDMA, and ketamine are being used increasingly in research and clinical settings. They also are being decriminalized and legalized by cities and states across the country. As research and access advance, a growing body of evidence suggests that one promising application for psychedelics is in the treatment of various types of trauma.

This panel will assemble doctors, lawyers, academics, entrepreneurs, and activists to discuss the emerging role of psychedelics in addressing the symptoms of racial trauma, post-traumatic stress disorder, and trauma associated with violence and emotional and sexual abuse. Panelists will address how psychedelics law and policy can help resolve or potentially exacerbate trauma.

Join the conversation and submit questions on Twitter @PetrieFlom using #POPLAR.

Panelists

  • Introduction: Carmel Shachar, Executive Director, The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School

Sponsored by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School with support from the Oswald DeN. Cammann Fund at Harvard University.